M-C Boily1, K Desai, B Masse, A Gumel. 1. Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College, London W2 1PG, UK. mc.boily@ic.ac.uk
Abstract
BACKGROUND: Male circumcision (MC) can reduce HIV acquisition. However, a better understanding of the indirect protective effect of MC on sexually transmitted infections (STIs) is required. OBJECTIVE: To assess the incremental benefits conferred by MC on HIV infection at the individual level in circumcision trials (no herd immunity effect) and at the population level (with herd immunity effect) owing to its protective effect against other STIs. METHODS: A dynamic stochastic model of HIV and STI infections in a Kenyan population was used to simulate the impact of MC offered to a few trial participants or to a large proportion of men in order to study the protective role of MC on HIV infection at the individual and population levels. RESULTS: Fewer than 20% of the HIV infections prevented in the circumcised arm of the circumcision trials (individual level) could be attributable to the efficacy of MC against STIs rather than against HIV. At the population level, MC can significantly reduce the prevalence of HIV, especially among men and women in the longer term. However, even at the population level, the long-term incremental impact of MC on HIV due to the protection against STI is modest (even if MC efficacy against the STI and STI prevalence was high). CONCLUSIONS: The protection of MC against STI contributes little to the overall effect of MC on HIV. Additional work is needed to determine whether, and under what conditions, the protective effect of MC efficacy against STIs can have a significant incremental benefit on the HIV epidemic.
BACKGROUND: Male circumcision (MC) can reduce HIV acquisition. However, a better understanding of the indirect protective effect of MC on sexually transmitted infections (STIs) is required. OBJECTIVE: To assess the incremental benefits conferred by MC on HIV infection at the individual level in circumcision trials (no herd immunity effect) and at the population level (with herd immunity effect) owing to its protective effect against other STIs. METHODS: A dynamic stochastic model of HIV and STI infections in a Kenyan population was used to simulate the impact of MC offered to a few trial participants or to a large proportion of men in order to study the protective role of MC on HIV infection at the individual and population levels. RESULTS: Fewer than 20% of the HIV infections prevented in the circumcised arm of the circumcision trials (individual level) could be attributable to the efficacy of MC against STIs rather than against HIV. At the population level, MC can significantly reduce the prevalence of HIV, especially among men and women in the longer term. However, even at the population level, the long-term incremental impact of MC on HIV due to the protection against STI is modest (even if MC efficacy against the STI and STI prevalence was high). CONCLUSIONS: The protection of MC against STI contributes little to the overall effect of MC on HIV. Additional work is needed to determine whether, and under what conditions, the protective effect of MC efficacy against STIs can have a significant incremental benefit on the HIV epidemic.
Authors: Jose Ricardo P Marins; Leda F Jamal; Sanny Y Chen; Marilisa B Barros; Esther S Hudes; Aristides A Barbosa; Pedro Chequer; Paulo R Teixeira; Norman Hearst Journal: AIDS Date: 2003-07-25 Impact factor: 4.177
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: Steven J Reynolds; Mary E Shepherd; Arun R Risbud; Raman R Gangakhedkar; Ronald S Brookmeyer; Anand D Divekar; Sanjay M Mehendale; Robert C Bollinger Journal: Lancet Date: 2004-03-27 Impact factor: 79.321
Authors: Colette Smit; Ronald Geskus; Daan Uitenbroek; Dieke Mulder; Anneke Van Den Hoek; Roel A Coutinho; Maria Prins Journal: Epidemiology Date: 2004-09 Impact factor: 4.822
Authors: Sten H Vermund; José A Tique; Holly M Cassell; Megan E Pask; Philip J Ciampa; Carolyn M Audet Journal: J Acquir Immune Defic Syndr Date: 2013-06-01 Impact factor: 3.731
Authors: Timothy B Hallett; Ramzi A Alsallaq; Jared M Baeten; Helen Weiss; Connie Celum; Ron Gray; Laith Abu-Raddad Journal: Sex Transm Infect Date: 2010-10-21 Impact factor: 3.519
Authors: Marie-Claude Boily; Benoît Mâsse; Ramzi Alsallaq; Nancy S Padian; Jeffrey W Eaton; Juan F Vesga; Timothy B Hallett Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069